- Home
- SACH vs VERU Comparison
SACH vs VERU Comparison
Compare SACH & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- VERU
- Stock Information
- Founded
- SACH 2010
- VERU 1971
- Country
- SACH United States
- VERU United States
- Employees
- SACH N/A
- VERU N/A
- Industry
- SACH Real Estate Investment Trusts
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- VERU Health Care
- Exchange
- SACH Nasdaq
- VERU Nasdaq
- Market Cap
- SACH 50.6M
- VERU 54.6M
- IPO Year
- SACH 2017
- VERU 1990
- Fundamental
- Price
- SACH $1.06
- VERU $2.56
- Analyst Decision
- SACH Hold
- VERU Strong Buy
- Analyst Count
- SACH 4
- VERU 3
- Target Price
- SACH $2.00
- VERU $33.33
- AVG Volume (30 Days)
- SACH 138.0K
- VERU 201.6K
- Earning Date
- SACH 11-05-2025
- VERU 12-15-2025
- Dividend Yield
- SACH 18.87%
- VERU N/A
- EPS Growth
- SACH N/A
- VERU N/A
- EPS
- SACH N/A
- VERU N/A
- Revenue
- SACH $4,046,000.00
- VERU $16,886,419.00
- Revenue This Year
- SACH N/A
- VERU N/A
- Revenue Next Year
- SACH $6.63
- VERU N/A
- P/E Ratio
- SACH N/A
- VERU N/A
- Revenue Growth
- SACH N/A
- VERU 337.24
- 52 Week Low
- SACH $0.80
- VERU $2.42
- 52 Week High
- SACH $2.24
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- SACH 40.74
- VERU 28.86
- Support Level
- SACH $1.04
- VERU $2.46
- Resistance Level
- SACH $1.10
- VERU $2.71
- Average True Range (ATR)
- SACH 0.03
- VERU 0.26
- MACD
- SACH 0.00
- VERU -0.17
- Stochastic Oscillator
- SACH 14.50
- VERU 7.54
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.